

Myocarditis

Bibliography of One Hundred Key Papers

selected by **Leslie T. Cooper, MD, FACC, FAHA**

Division of Cardiovascular Diseases - Mayo Clinic - Rochester - Minnesota – USA

-
- Abdel-Aty H, Boye P, Zagrosek A, et al.** *Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches.*
J Am Coll Cardiol. 2005;45:1815-1822.
-
- Amabile N, Fraisse A, Bouvenot J, Chetaille P, Ovaert C.** *Outcome of acute fulminant myocarditis in children.*
Heart. 2006;92:1269-1273.
-
- Andreoletti L, Venteo L, Douche-Aourik F, et al.** *Active Coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction.*
J Am Coll Cardiol. 2007;50:2207-2214.
-
- Angelini A, Calzolari V, Calabrese F, et al.** *Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis.*
Heart. 2000;84:245-250.
-
- Aretz HT, Billingham ME, Edwards WD, et al.** *Myocarditis. A histopathologic definition and classification.*
Am J Cardiovasc Pathol. 1987;1:3-14.
-
- Arness M, Eckart R, Love S, et al.** *Myopericarditis following smallpox vaccination.*
Am J Epidemiol. 2004;160:642-651.
-
- Badorff C, Knowlton KU.** *Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside.*
Med Microbiol Immunol. 2004;193:121-126.
-
- Badorff C, Lee G, Lamphear B, et al.** *Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.*
Nat Med. 1999;5:320-326.
-
- Barton M, Finkelstein Y, Opavsky M, et al.** *Eosinophilic myocarditis temporally associated with conjugate meningococcal C and hepatitis B vaccines in children.*
Pediatr Infect Dis J. 2008;27:831-835.
-
- Baughman KL.** *Diagnosis of myocarditis: death of Dallas criteria.*
Circulation. 2006;113:593-595.
-
- Beck MA, Shi Q, Morris VC, Levander OA.** *Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates.*
Nat Med. 1995;1:433-436.
-

Bibliography of One Hundred Key Papers

- Bergelson J, Cunningham J, Drouguett G, et al.** *Isolation of a common receptor for Coxsackie B virus and adenoviruses types 2 and 5.* **Science.** 1997;275:1320-1323.
-
- Bowles N, Richardson P, Olsen E, Archard L.** *Detection of Coxsackie B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy.* **Lancet.** 1986;1:1120-1122.
-
- Bowles NE, Ni J, Marcus F, Towbin JA.** *The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.* **J Am Coll Cardiol.** 2002;39:892-895.
-
- Cabinian AE, Kiel RJ, Smith F, Ho KL, Khatib R, Reyes MP.** *Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model.* **J Lab Clin Med.** 1990;115:454-462.
-
- Caforio A, Calabrese F, Angelini A, et al.** *A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis.* **Eur Heart J.** 2007;28:1326-1333.
-
- Caforio AL, Mahon NJ, Tona F, McKenna WJ.** *Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.* **Eur J Heart Fail.** 2002;4:411-417.
-
- Chapman NM, Kim KS.** *Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy.* **Curr Top Microbiol Immunol.** 2008;323:275-292.
-
- Cheung P, Yuan J, Zhang H, et al.** *Specific interactions of mouse organ proteins with the 5'untranslated region of coxsackievirus B3: potential determinants of viral tissue tropism.* **J Med Virol.** 2005;77:414-424.
-
- Chimenti C, Pieroni M, Maseri A, Frustaci A.** *Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia.* **J Am Coll Cardiol.** 2004; 43:2305-2313.
-
- Chow LH, Radio SJ, Sears TD, McManus BM.** *Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis.* **J Am Coll Cardiol.** 1989;14:915-920.
-
- Cooper L, Baughman K, Brutsaert D, et al.** *The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.* **Circulation.** 2007;116:2216-2233.
-
- Cooper L, Rader V, Ralston N.** *The roles of selenium and mercury in the pathogenesis of viral cardiomyopathy.* **J Card Fail.** 2007;13:193-199.
-
- Cooper LT, Berry GJ, Shabetai R.** *Giant cell myocarditis: natural history and treatment.* **N Engl J Med.** 1997;336:1860-1866.
-
- Corssmit EP, Trip MD, Durrer JD.** *Löffler's endomyocarditis in the idiopathic hypereosinophilic syndrome.* **Cardiology.** 1999;91:272-276.
-



- Coyne CB, Bergelson JM.** *Virus-induced Abl and Fyn kinase signals permit Coxsackie virus entry through epithelial tight junctions.* **Cell.** 2006;124:119-131.
-
- Dec G, Palacios I, Fallon J, et al.** *Active myocarditis in the spectrum of acute dilated cardiomyopathies.* **N Engl J Med.** 1985;312:885-890.
-
- Drucker NA, Colan SD, Lewis AB, et al.** *Gamma-globulin treatment of acute myocarditis in the pediatric population.* **Circulation.** 1994;89:252-257.
-
- Eriksson U, Ricci R, Hunziker L, et al.** *Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity.* **Nat Med.** 2003;9:1484-1490.
-
- Fabre A, Sheppard MN.** *Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death.* **Heart.** 2006;92:316-320.
-
- Fairweather D, Frisancho-Kiss S, Gatewood S, et al.** *Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection.* **Autoimmunity.** 2004;37:131-145.
-
- Fairweather D, Frisancho-Kiss S, Rose N.** *Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis.* **Rev Med Virol.** 2005;15:17-27.
-
- Farrar DJ, Holman WR, McBride LR, et al.** *Long-term follow-up of thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function.* **J Heart Lung Transplant.** 2002;21:516-521.
-
- Felker GM, Boehmer JP, Hruban RH, et al.** *Echocardiographic findings in fulminant and acute myocarditis.* **J Am Coll Cardiol.** 2000;36:227-232.
-
- Friedrich MG, Sechtem U, Schulz-Menger J, et al; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis.** *Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.* **J Am Coll Cardiol.** 2009;53:1475-1487.
-
- Frisancho-Kiss S, Davis S, Nyland J, et al.** *Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease.* **J Immunol.** 2007;178:6710-6714.
-
- Frustaci A, Russo MA, Chimenti C.** *Randomized study of the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study.* **Eur Heart J.** 2009;30:1995-2002.
-
- Frustaci A, Verardo R, Caldarulo M, Acconcia M, Russo M, Chimenti C.** *Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration.* **Eur Heart J.** 2007;28:733-740.
-
- Fuse K, Chan G, Liu Y, et al.** *Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production.* **Circulation.** 2005;112:2276-2285.
-
- Gauntt CJ, Pallansch MA.** *Coxsackievirus B3 clinical isolates and murine myocarditis.* **Virus Res.** 1996;41:89-99.

Bibliography of One Hundred Key Papers

- Gutberlet M, Spors B, Thoma T, et al.** *Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence.*
Radiology. 2008;246:401-409.
-
- Hare JM, Baughman KL.** *Fulminant and acute lymphocytic myocarditis: the prognostic value of clinicopathological classification.*
Eur Heart J. 2001;22:269-270.
-
- Herskowitz A, Ahmed-Ansari A, Neumann DA, et al.** *Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis.*
J Am Coll Cardiol. 1990;15:624-632.
-
- Holzmann M, Nicko A, Kühl U, et al.** *Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period.*
Circulation. 2008;118:1722-1728.
-
- Huber S, Feldman A, Sartini D.** *Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice.*
Circ Res. 2006;99:1109-1116.
-
- Huber SA, Budd RC, Rossner K, Newell MK.** *Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy.*
Ann N Y Acad Sci. 1999;887:181-190.
-
- Hufnagel G, Maisch B.** *Expression of MHC class I and II antigens and the II-2 receptor in rejection, myocarditis and dilated cardiomyopathy.*
Eur Heart J. 1991;12(suppl D):137-140.
-
- Kilgallen C, Jackson E, Bankoff M, Salomon R, Surks H.** *A case of giant cell myocarditis and malignant thymoma: a post-mortem diagnosis by needle biopsy.*
Clin Cardiol. 1998;21:48-51.
-
- Kim K, Tracy S, Tapprich W, et al.** *5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.*
J Virol. 2005;79:7024-7041.
-
- Kindermann I, Kindermann M, Kandolf R, et al.** *Predictors of outcome in patients with suspected myocarditis.*
Circulation. 2008;118:639-648.
-
- Kühl U, Pauschinger M, Noutsias M, et al.** *High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction.*
Circulation. 2005;111:887-893.
-
- Kühl U, Pauschinger M, Schwimmbeck P, et al.** *Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction.*
Circulation. 2003;107:2793-2798.
-
- Kühl U, Pauschinger M, Seeberg B, et al.** *Viral persistence in the myocardium is associated with progressive cardiac dysfunction.*
Circulation. 2005;112:1965-1970.
-
- Lauer B, Niederau C, Kühl U, et al.** *Cardiac troponin T in patients with clinically suspected myocarditis.*
J Am Coll Cardiol. 1997;30:1354-1359.
-



-
- Li Y, Bourlet T, Andreoletti L, et al.** *Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy.*
Circulation. 2000;101:231-234.
-
- Li Y, Heuser J, Cunningham L, Kosanke S, Cunningham M.** *Mimicry and antibody-mediated cell signaling in autoimmune myocarditis.*
J Immunol. 2006;177:8234-8240.
-
- Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL.** *Clinicopathologic description of myocarditis.*
J Am Coll Cardiol. 1991;18:1617-1626.
-
- Liu P, Mason J.** *Advances in the understanding of myocarditis.*
Circulation. 2001;104:1076-1082.
-
- Magnani JW, Danik HJ, Dec GW Jr, DiSalvo TG.** *Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors.*
Am Heart J. 2006;151:463-470.
-
- Magnani JW, Dec GW.** *Myocarditis: current trends in diagnosis and treatment.*
Circulation. 2006;113:876-890.
-
- Mahrholdt H, Goedecke C, Wagner A, et al.** *Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology.*
Circulation. 2004;109:1250-1258.
-
- Mahrholdt H, Wagner A, Deluigi C, et al.** *Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.*
Circulation. 2006;114:1581-1590.
-
- Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S.** *Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report.*
Herz. 2000;25:200-209.
-
- Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE.** *Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome.*
J Am Coll Cardiol. 2005;45:1340-1345.
-
- Mason JW, O'Connell JB, Herskowitz A, et al.** *A clinical trial of immunosuppressive therapy for myocarditis.*
N Engl J Med. 1995;333:269-275.
-
- Matsumori A, Crumpacker CS, Abelmann WH.** *Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model.*
J Am Coll Cardiol. 1987;9:1320-1325.
-
- Matsumori A, Shimada T, Chapman N, Tracy S, Mason J.** *Myocarditis and heart failure associated with hepatitis C virus infection.*
J Card Fail. 2006;12:293-298.
-
- Matsumori A.** *Hepatitis C virus infection and cardiomyopathies.*
Circ Res. 2005;96:144-147.
-
- McAlister HF, Klementowicz PT, Andrews C, Fisher JD, Feld M, Furman S.** *Lyme carditis: an important cause of reversible heart block.*
Ann Intern Med. 1989;110:339-345.
-
- McCarthy RE III, Boehmer JP, Hruban RH, et al.** *Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.*
N Engl J Med. 2000;342:690-695.
-

Bibliography of One Hundred Key Papers

- McNamara DM, Holubkov R, Starling RC, et al.** *Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.*
Circulation. 2001;103:2254-2259.
-
- Mendes LA, Dec GW, Picard MH, Palacios IF, Newell J, Davidoff R.** *Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis.*
Am Heart J. 1994;128:301-307.
-
- Mendes LA, Picard MH, Dec GW, Hartz VL, Palacios IF, Davidoff R.** *Ventricular remodeling in active myocarditis. Myocarditis Treatment Trial.*
Am Heart J. 1999;138(2 pt 1):303-308.
-
- Moloney ED, Egan JJ, Kelly P, Wood AE, Cooper LT Jr.** *Transplantation for myocarditis: a controversy revisited.*
J Heart Lung Transplantation. 2005;24:1103-1110.
-
- Morgera T, Di Lenarda A, Dreas L, et al.** *Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes.*
Am Heart J. 1992;124:455-467.
-
- Nakashima H, Katayama T, Ishizaki M, Takeno M, Honda Y, Yano K.** *Q wave and non-Q wave myocarditis with special reference to clinical significance.*
Jpn Heart J. 1998;39:763-774.
-
- Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kühl U.** *Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives.*
Expert Rev Cardiovasc Ther. 2004;2:37-51.
-
- Nugent AW, Daubeney PEF, Chondros P, et al.** *The epidemiology of childhood cardiomyopathy in Australia.*
N Engl J Med. 2003;348:1639-1646.
-
- Okada I, Matsumori A, Matoba Y, et al.** *Combination treatment with ribavirin and interferon for coxsackie B3 replication.*
J Lab Clin Med. 1992;120:569-573.
-
- Ono M, Shimizu J, Miyachi Y, Sakaguchi S.** *Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells.*
J Immunol. 2006;176:4748-4756.
-
- Opavsky MA, Penninger J, Aitken K, et al.** *Susceptibility to myocarditis is dependent on the response of alpha/beta T lymphocytes to coxsackie viral infection.*
Circ Res. 1999;85:551-558.
-
- Pallansch M.** *Coxsackievirus B epidemiology and public health concerns.*
Curr Top Microbiol Immunol. 1997;223:13-30.
-
- Parrillo J, Cunnion R, Epstein S, et al.** *A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy.*
N Engl J Med. 1989;321:1061-1068.
-
- Perens G, Levi D, Alejos J, Wetzel G.** *Muronomab-CD3 for pediatric acute myocarditis.*
Pediatr Cardiol. 2007;28:21-26.
-
- Rangachari M, Mauermann N, Marty R, et al.** *T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17.*
J Exp Med. 2006;203:2009-2019.
-



-
- Rassi A Jr, Rassi A, Little WC, et al.** *Development and validation of a risk score for predicting death in Chagas' heart disease.*
N Engl J Med. 2006;355:799-808.
-
- Ray CG, Icenogle TB, Minnich LL, Copeland JG,** *The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis.*
J Infect Dis. 1989;159:829-836.
-
- Sakaguchi S.** *Regulatory T cells: key controllers of immunologic self-tolerance.*
J Infect Dis. 1989;159:829-836.
-
- Schulze K, Becker BF, Schauer R, Schultheiss HP.** *Antibodies to ADP-ATP carrier—an autoantigen in myocarditis and dilated cardiomyopathy—impair cardiac function.*
Circulation. 1990;81:959-969.
-
- Schwartz J, Sartini D, Huber S.** *Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection.*
Virology. 2004;330:16-23.
-
- Smith SC, Ladenson JH, Mason JW, Jaffe AS.** *Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates.*
Circulation. 1997;95:163-168.
-
- Tam P.** *Coxsackievirus myocarditis: Interplay between virus and host in the pathogenesis of heart disease.*
Viral Immunol. 2006;19:133-146.
-
- Topkara VK, Dang NC, Barili F, et al.** *Ventricular assist device use for the treatment of acute viral myocarditis.*
J Thorac Cardiovasc Surg. 2006;131:1190-1191.
-
- Towbin JA, Lowe AM, Colan SD, et al.** *Incidence, causes, and outcomes of dilated cardiomyopathy in children.*
JAMA. 2006;296:1867-1876.
-
- Tracy S, Hofling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ.** *Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice.*
J Med Virol. 2000;62:70-81.
-
- Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al.** *Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.*
Circulation. 2001;104:39-45.
-
- Yazaki Y, Isobe M, Hiramitsu S, et al.** *Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy.*
Am J Cardiol. 1998;82:537-540.
-
- Zipes D, Camm A, Borggrefe M, et al.** *ACC/AHA/ESC 2006 Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.*
Circulation. 2006;114:e385-e484.
-

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in **English**. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be abbreviated according to the **Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg.* 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation.* 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

LEAD ARTICLE

The lead article should not exceed 30 standard typed pages (7000 to 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 15 standard typed pages (3000 to 4000 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

FASCINOMA CARDIOLOGICA ARTICLES

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.
